Last updated: September 8, 2026
Acetaminophen/oxycodone hydrochloride is a mature, immediate-release opioid combination marketed under brand names including Percocet and by numerous generic manufacturers. Its core composition patents and regulatory exclusivities have expired. The market is driven by generic volume, pharmacy access, opioid prescribing controls, supply reliability, wholesaler contracts, and state-level restrictions rather than patent protection.
Public companies generally do not disclose revenue for this combination separately. Financial exposure is therefore best assessed through prescription volume, generic pricing, opioid-market trends, manufacturing capacity, litigation costs, and product mix.
What is acetaminophen/oxycodone hydrochloride?
Acetaminophen/oxycodone hydrochloride combines an opioid analgesic with acetaminophen for short-term treatment of moderate to severe pain.
| Attribute |
Market profile |
| Active ingredients |
Acetaminophen and oxycodone hydrochloride |
| Primary dosage form |
Immediate-release oral tablet |
| Common strengths |
2.5/325 mg, 5/325 mg, 7.5/325 mg, and 10/325 mg |
| Historical brand |
Percocet |
| Regulatory category |
Prescription opioid, Schedule II |
| Primary market |
U.S. generic prescription market |
| Reference product |
Percocet and related approved reference products |
| Patent position |
Core composition and early product patents expired |
| Current exclusivity |
No meaningful market exclusivity for the mature immediate-release combination |
The principal commercial distinction is between oxycodone strength and acetaminophen content. The 10 mg/325 mg tablet has historically been important for patients requiring higher opioid doses, while the 5 mg/325 mg strength is widely used in outpatient prescribing.
The FDA has emphasized limiting total daily acetaminophen exposure because excessive use can cause severe liver injury. Combination opioid products also carry risks of respiratory depression, misuse, addiction, overdose, and diversion.[1]
What patents protect acetaminophen/oxycodone hydrochloride?
No active core patent is generally understood to block generic immediate-release acetaminophen/oxycodone tablets in the United States. The original product patents and associated regulatory exclusivities expired long ago.
Patent and exclusivity timeline
| Event |
Approximate timing |
Commercial effect |
| Initial oxycodone/acetaminophen combination approvals |
1970s |
Brand market established |
| Percocet commercialization |
1970s and later |
Brand recognition and physician familiarity |
| Original composition and product protection |
Expired decades ago |
Generic entry permitted |
| Generic approvals |
Beginning in the 1990s and expanding thereafter |
Price competition intensified |
| Current market |
Mature generic market |
No core patent-based barrier |
The FDA Orange Book identifies patents and regulatory exclusivity for approved products, but mature acetaminophen/oxycodone immediate-release products do not have a current Orange Book patent position comparable to newer branded medicines.[2]
What formulations are protected by patents?
The standard immediate-release tablet is not protected by a commercially meaningful active patent estate. Potentially protectable subject matter can include:
- Abuse-deterrent delivery systems.
- Modified-release oxycodone formulations.
- Distinctive tablet compositions.
- Manufacturing processes.
- Packaging or tamper-resistant systems.
- New dosage forms or delivery devices.
These rights would not necessarily block conventional generic acetaminophen/oxycodone immediate-release tablets. A formulation patent covering extended-release oxycodone or an abuse-deterrent platform would protect a different product category.
The main commercial alternatives are standalone oxycodone products, non-opioid analgesics, tramadol, hydrocodone/acetaminophen, and abuse-deterrent or extended-release oxycodone products. These products do not create patent-based exclusivity for the conventional combination.
When does acetaminophen/oxycodone lose exclusivity?
Acetaminophen/oxycodone hydrochloride lost practical market exclusivity decades ago. There is no single upcoming patent cliff comparable to the loss of exclusivity for a recently launched branded drug.
The market is already in the post-exclusivity phase:
- Multiple generic manufacturers compete on price and supply.
- Retail reimbursement is governed by payer and wholesaler contracts.
- Prescribing volumes are influenced by opioid-control policies.
- Manufacturers compete on manufacturing reliability and regulatory compliance.
- Brand Percocet retains limited value through name recognition but does not control the market.
Because the product is a Schedule II controlled substance, generic entry still requires FDA approval, Drug Enforcement Administration registration, quota compliance, controlled-substance security, and compliance with state prescribing laws. Those requirements create operational barriers but not patent exclusivity.
What is the Orange Book status of acetaminophen/oxycodone hydrochloride?
The Orange Book lists approved products and identifies patents and exclusivity associated with those products. For mature immediate-release acetaminophen/oxycodone products, the important commercial conclusion is that the market has broad generic availability and no known active core patent that prevents substitution.
An Orange Book listing does not guarantee commercial protection. A patent can be listed against an individual reference product while having limited practical relevance to other approved products. For this combination, the historic product architecture is sufficiently old that commercial competition is primarily generic.
Are there Paragraph IV challenges for acetaminophen/oxycodone?
Paragraph IV litigation is not a significant current market driver for conventional immediate-release acetaminophen/oxycodone. Paragraph IV certifications are most commercially important when a branded product has unexpired listed patents and an ANDA applicant seeks an early generic launch.
For this mature combination:
- Core patents have expired.
- Generic versions have been approved for many years.
- No meaningful 180-day first-filer event drives the current market.
- Litigation risk is more likely to concern manufacturing, labeling, distribution, controlled-substance compliance, or product liability than core composition patents.
A manufacturer pursuing a new formulation could face Paragraph IV litigation if the proposed product references a newer branded product with listed patents. That analysis would apply to the newer formulation, not to the conventional immediate-release combination.
How many patents cover acetaminophen/oxycodone?
The historical product has been associated with numerous patents across brands, formulations, manufacturing processes, and later oxycodone products. The number of historical patent documents is not a useful measure of current protection.
For commercial analysis, the relevant count is the number of unexpired, enforceable patents that could block an FDA-approved generic immediate-release tablet. That number is effectively zero for the mature conventional combination based on its long generic history and lack of a current core Orange Book barrier.[2]
Process or formulation patents may still affect a particular manufacturer. They normally do not prevent other companies from producing an equivalent tablet using a different process or formulation.
What is the FDA regulatory status?
The product is FDA-approved in multiple immediate-release strengths and is regulated as a Schedule II controlled substance.
Key regulatory constraints include:
- Required prescription status.
- No refills under federal controlled-substance rules.
- Controlled-substance ordering, storage, recordkeeping, and distribution requirements.
- FDA labeling requirements for opioid risks.
- Acetaminophen liver-toxicity warnings.
- Postmarketing surveillance and opioid risk-management obligations.
- State-level prescribing limits and electronic-prescribing rules.
FDA opioid policy has reduced commercial flexibility. Labeling, supply-chain monitoring, prescriber education, and abuse-prevention controls increase compliance costs. They also limit the ability of manufacturers to expand demand through conventional promotional activity.[1]
How large is the market?
The U.S. market remains substantial in unit terms but has a declining structural profile compared with the pre-2012 opioid market.
The main volume trends are:
| Driver |
Direction |
Effect on acetaminophen/oxycodone |
| Opioid prescribing rates |
Down from historical peaks |
Reduces prescription volume |
| Generic competition |
High |
Reduces unit prices |
| Post-surgical prescribing limits |
More restrictive |
Reduces days supplied |
| Acute pain treatment |
Persistent |
Supports baseline demand |
| Opioid stewardship |
Increasing |
Constrains refills and dosage |
| Product shortages |
Periodic |
Creates temporary share shifts |
| Brand substitution |
Limited |
Preserves generic dominance |
The Centers for Disease Control and Prevention reported a long-term reduction in opioid prescribing from its 2012 peak, although prescribing remains common in acute pain settings.[3] Oxycodone combination products continue to be used after surgery, dental procedures, trauma, and other acute pain events, but treatment duration is generally shorter than in earlier market periods.
Public data do not provide a reliable, standalone annual revenue figure for all acetaminophen/oxycodone products. Prescription volume and net sales are divided among private-label suppliers, branded manufacturers, specialty distributors, wholesalers, and retail pharmacies.
What is the financial trajectory?
The financial trajectory is mature to declining in volume and highly competitive in price. Revenue growth is unlikely to come from market expansion. It is more likely to come from temporary supply disruptions, contract wins, product availability, manufacturing efficiency, or adjacent dosage forms.
Revenue characteristics
| Financial variable |
Expected market behavior |
| Gross sales |
Stable to declining over time |
| Net price |
Low and pressured by generic competition |
| Gross margin |
Variable, dependent on scale and compliance costs |
| Volume |
Declining over the long term, with episodic rebounds |
| Working capital |
Influenced by controlled-substance inventory requirements |
| Litigation expense |
Material risk for large opioid suppliers |
| Customer concentration |
High through wholesalers, group purchasing organizations, and pharmacy chains |
| Brand premium |
Limited for conventional Percocet |
| Supply-driven pricing |
Possible during shortages |
Generic manufacturers can achieve acceptable returns when they have low-cost production, reliable API supply, and distribution scale. The product is less attractive for companies with high overhead, weak controlled-substance compliance systems, or limited access to U.S. pharmacy channels.
For branded or specialty manufacturers, the combination is unlikely to support premium pricing without a differentiated product. A reformulated product with abuse-deterrent characteristics, a novel delivery system, or a clinical advantage could command better economics, but it would carry higher development, regulatory, and reimbursement risk.
Which companies compete in the market?
Competition includes large generic manufacturers, specialty pharmaceutical companies, and contract manufacturers. Market participation can change because of product discontinuations, FDA actions, quota limitations, opioid settlements, and supply agreements.
Companies historically associated with oxycodone or opioid generic markets include:
- Teva Pharmaceuticals.
- Mallinckrodt Pharmaceuticals.
- Hikma Pharmaceuticals.
- Amneal Pharmaceuticals.
- Endo and Par Pharmaceutical.
- Rhodes Pharmaceuticals.
- Sun Pharmaceutical Industries.
- KVK-Tech.
- Sandoz and other generic suppliers.
The precise supplier ranking varies by dosage strength, channel, state, wholesaler contract, and time period. A manufacturer may have FDA approval but limited commercial share if it lacks active distribution or controlled-substance quota.
What manufacturing and intellectual-property barriers exist?
The largest barriers are operational rather than patent-based.
Active pharmaceutical ingredient supply
Oxycodone hydrochloride is a controlled opioid API. Supply is subject to DEA production quotas, import controls, supplier qualification, and heightened security requirements. A disruption affecting API production can reduce finished-dose availability even when demand remains stable.
Acetaminophen is widely available and is not the principal supply constraint. The more important manufacturing risks involve oxycodone API allocation, tablet production capacity, quality systems, and regulatory inspections.
Manufacturing compliance
Manufacturers must manage:
- Controlled-substance inventory reconciliation.
- Diversion controls.
- Serialization and traceability requirements.
- Content uniformity and dissolution testing.
- Cross-contamination controls.
- Stability and packaging requirements.
- FDA inspection readiness.
- Wholesaler monitoring.
These obligations can increase fixed costs and discourage smaller manufacturers from entering the market.
Intellectual-property barriers
Remaining IP opportunities are narrow. A company may pursue protection for:
- Lower-acetaminophen formulations.
- Abuse-deterrent tablets.
- Improved disintegration or dissolution.
- New combinations with non-opioid analgesics.
- Packaging and tamper-evident systems.
- Manufacturing processes.
Such rights generally support differentiated products rather than the conventional generic tablet.
What generic entry risks exist?
Generic entry risk is already realized rather than impending. The commercial risks now run in the opposite direction: manufacturers may exit, lose supply capacity, or face regulatory restrictions.
The most important risks are:
- Continued opioid-volume decline.
- Further reimbursement pressure.
- Product recalls or manufacturing observations.
- DEA quota limitations.
- Opioid litigation and settlement payments.
- Pharmacy and wholesaler restrictions.
- State prescribing caps.
- Substitution toward non-opioid treatments.
- Temporary shortages that increase service requirements.
- Reputational and compliance costs.
A new generic entrant would face low patent risk but high commercial risk. It would need dependable supply, regulatory infrastructure, and distribution access to gain share in a low-price market.
What patent litigation affects the product?
No current patent litigation appears to define the conventional acetaminophen/oxycodone immediate-release market. Litigation exposure is more likely to arise from:
- Opioid marketing and distribution claims.
- Product-liability actions.
- Government investigations.
- Controlled-substance compliance.
- Manufacturing deviations.
- Labeling disputes.
- Contract and supply disagreements.
Large opioid manufacturers have faced extensive federal, state, municipal, and private litigation. Settlement obligations can affect corporate cash flow even when the underlying product remains approved and commercially available.[4]
How does acetaminophen/oxycodone compare with hydrocodone/acetaminophen?
| Factor |
Acetaminophen/oxycodone |
Hydrocodone/acetaminophen |
| Opioid ingredient |
Oxycodone HCl |
Hydrocodone bitartrate |
| Regulatory schedule |
Schedule II |
Schedule II |
| Common brand association |
Percocet |
Vicodin, Norco |
| Patent position |
Mature, generic |
Mature, generic |
| Typical use |
Moderate to severe acute pain |
Moderate to severe acute pain |
| Market trend |
Declining from historical levels |
Declining from historical levels |
| Pricing |
Generic and competitive |
Generic and competitive |
| Core commercial risk |
Opioid controls and supply |
Opioid controls and supply |
| Differentiation |
Limited in standard tablets |
Limited in standard tablets |
Oxycodone is often perceived as a stronger opioid on a milligram-equivalent basis, which can influence prescribing and regulatory scrutiny. Both combinations face the same broad pressure from opioid stewardship and non-opioid alternatives.
What is the outlook for investors and pharmaceutical companies?
The conventional product is a cash-flow and supply-chain business, not an innovation-led patent asset.
Investment attractiveness depends on:
- Manufacturing cost.
- FDA compliance history.
- Controlled-substance quota access.
- Distribution contracts.
- Ability to maintain uninterrupted supply.
- Exposure to opioid litigation.
- Portfolio diversification.
- Access to differentiated formulations.
A company with a low-cost facility and strong U.S. generic distribution may generate stable but modest returns. A company relying on premium pricing or volume growth faces a weak outlook. The better strategic opportunities are adjacent products with lower abuse liability, lower acetaminophen exposure, or non-opioid mechanisms, although those products require new clinical and regulatory investment.
Key Takeaways
- Acetaminophen/oxycodone hydrochloride is a mature generic opioid combination.
- Core patent and regulatory exclusivity expired decades ago.
- No meaningful current patent barrier blocks conventional immediate-release generic entry.
- Paragraph IV litigation is not a central current market issue.
- Revenue is fragmented and is not separately reported by most manufacturers.
- Long-term prescription volume is under pressure from opioid-control policies.
- Generic pricing is highly competitive.
- The principal barriers are controlled-substance regulation, DEA quotas, API supply, compliance, and distribution.
- Financial performance depends on supply reliability and manufacturing efficiency rather than patent exclusivity.
- Differentiated formulations may support better economics but carry higher development and regulatory risk.
FAQs
Is Percocet still patent protected?
No. The core immediate-release acetaminophen/oxycodone combination has been generic for decades. Any surviving patents would generally concern a specific formulation, manufacturing process, or delivery system rather than the basic combination.
Can a generic company launch acetaminophen/oxycodone without a patent settlement?
For a conventional immediate-release generic product, the market is already open and populated by approved generic manufacturers. A patent settlement would be relevant only if the proposed product referenced a newer product with unexpired listed patents.
Does oxycodone/acetaminophen have biosimilar competition?
No. Biosimilars apply to biological products. Acetaminophen/oxycodone is a chemically synthesized small-molecule drug and competes through the abbreviated new drug application pathway.
Why can acetaminophen/oxycodone experience shortages after patent expiry?
Shortages can result from DEA quotas, API disruptions, manufacturing failures, recalls, plant closures, quality-control observations, or wholesaler allocation decisions. Patent expiry does not guarantee redundant manufacturing capacity.
Is the combination financially attractive for a pharmaceutical manufacturer?
It can provide recurring generic revenue for a scaled manufacturer with compliant controlled-substance operations and reliable distribution. It is generally unattractive as a standalone growth asset because volume is under regulatory pressure, pricing is competitive, and litigation exposure can be significant.
References
- U.S. Food and Drug Administration. (2023). Opioid analgesic medications: Drug safety communications and labeling information. https://www.fda.gov
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. https://www.fda.gov
- Centers for Disease Control and Prevention. (2024). U.S. opioid dispensing rate maps and prescribing data. https://www.cdc.gov
- U.S. Department of Justice. (2023). Opioid litigation and enforcement actions. https://www.justice.gov
